Mana.bio

Executive Summary

Mana.bio is an Israeli AI-driven biotechnology company pioneering the design and manufacturing of lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. By integrating machine learning, high-throughput synthesis, and automated screening, Mana.bio creates tissue-targeted, extra-hepatic LNPs that overcome the traditional liver tropism of standard LNP formulations. This platform has the potential to unlock the full therapeutic promise of gene therapy, RNA therapeutics, and vaccines by enabling precise delivery to a wide range of target tissues. Founded in 2020 and headquartered in Tel Aviv, the company operates at the platform stage, focusing on building a versatile delivery technology that can be partnered with multiple drug developers. Mana.bio’s proprietary AI engine enables rapid optimization of LNP compositions, reducing the time and cost associated with conventional trial-and-error approaches. The company’s ability to screen thousands of formulations in parallel positions it as a key enabler in the growing field of extrahepatic gene delivery. While still private and likely pre-revenue, Mana.bio has attracted attention from the biopharma industry due to the high unmet need for targeted LNP systems. Successful validation of its platform in vivo and strategic partnerships could accelerate the transition from platform development to therapeutic applications, making Mana.bio a notable player in the next wave of gene and nucleic acid medicines.

Upcoming Catalysts (preview)

• Q3 2026Partnership Announcement with Major Pharma for LNP Development50% success
• Q2 2026Series A Funding Round Closure70% success
• Q4 2026Publication of In Vivo Data Demonstrating Extrahepatic Targeting60% success